title: Exenatide once weekly in type 2 diabetes mellitus.
authors.forename: Lindsay A
authors.initials: LA
authors.lastname: Bischoff
authors.forename: Serge A
authors.initials: SA
authors.lastname: Jabbour
authors.forename: Jeffrey L
authors.initials: JL
authors.lastname: Miller
mesh_terms: D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000378:metabolism; D004334:Drug Administration Schedule; D000077270:Exenatide; D052216:Glucagon-Like Peptide 1 / Q000378:metabolism; D000067757:Glucagon-Like Peptide-1 Receptor; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage* / Q000191:economics; D010455:Peptides / Q000008:administration & dosage* / Q000191:economics; D018027:Receptors, Glucagon / Q000819:agonists; D013997:Time Factors; D016896:Treatment Outcome; D014688:Venoms / Q000008:administration & dosage* / Q000191:economics
chemical_list: C000593833:GLP1R protein, human; D000067757:Glucagon-Like Peptide-1 Receptor; D007004:Hypoglycemic Agents; D010455:Peptides; D018027:Receptors, Glucagon; D014688:Venoms; D052216:Glucagon-Like Peptide 1; D000077270:Exenatide